Psoriatic Arthritis Pipeline, Clinical Trials, FDA Approvals and Emerging Drugs 2023 (Updated)

DelveInsight's “Psoriatic Arthritis Pipeline Insight 2023” report provides comprehensive information on more than 50 companies and more than 50 drugs in development in the psoriatic arthritis landscape. Covers drug profiles in development for psoriatic arthritis, including clinical and non-clinical stage products. It also covers the therapeutic evaluation of psoriatic arthritis by product type, stage, route of administration, and molecule type. Further highlights inactive pipeline products in this space.

Key takeaways from the psoriatic arthritis development report

• DelveInsight's Psoriatic Arthritis Development Report shows a robust space with more than 50 active players working to develop more than 50 therapies in development for the treatment of psoriatic arthritis.
• Leading companies working in the psoriatic arthritis market include Mylan, Celltrion, Fresenius Kabi, Pfizer, Fujifilm Kyowa Kirin Biologics, Amgen, Zydus cedilla, Sandoz, Shanghai Henlius Biotech, Hetero Biopharma, CinnaGen, Fresenius Kabi, Torrent Pharmaceuticals, Cipla , Biogen, AbbVie, Biocad, Boehringer Ingelheim, Sun Pharma Global, Gilead Sciences, UCB Biopharma, Formycon, Bristol-Myers Squibb, AbGenomics, Boehringer Ingelheim, Affibody, AltruBio, Bio-Thera Solutions, Dong-A ST, Synact Pharma, NeuClone , 3SBio, Qyuns Therapeutics, Kangpu Biopharmaceuticals, Alpine Immune Sciences, Akeso Biopharma, Polpharma Biologics, Avotres, Bio-Thera Solutions, Xbrane Biopharma, XBiotech, Innovimmune Biotherapeutics, Aclaris Therapeutics, Luye Pharma Group, Evelo, Levolta Pharmaceuticals, DNX Biopharmaceuticals, Mycenax Biotech et al.
• Promising therapies for psoriatic arthritis at various stages of development include NDI-034858, Alefacept, Methotrexate, Etanercept, UCB4940 40 mg, Methotrexate (MTX), and others.
• September 2023: ACELYRIN Inc. announced a Phase 2 and 3 clinical trial study for Izokibep. Izokibep is a potent and selective interleukin (IL)-17A inhibitor that is being developed for the treatment of psoriatic arthritis (PsA). This study will evaluate the efficacy of izokibep in subjects with PsA.
• September 2023: Novartis Pharmaceuticals announced a Phase 3 clinical trial study for Secukinumab and Ustekinumab. The purpose of this study is to compare the safety and efficacy of secukinumab and ustekinumab in patients with active psoriatic arthritis who failed previous treatment with TNFα inhibitors.

Request a sample and discover recent advances in medications for the treatment of psoriatic arthritis @ Report on the development of psoriatic arthritis

In the psoriatic arthritis pipeline report, a detailed description of the drug is provided including the mechanism of action of the drug, clinical studies, NDA approvals (if applicable) and product development activities comprising the technology, collaborations, licenses, psoriatic arthritis mergers and acquisitions. , financing, designations and other details related to the product.

Psoriatic Arthritis Overview

Psoriatic arthritis is a chronic inflammatory joint disease that may be associated with psoriasis. It can affect both peripheral joints and the axial skeleton, causing pain, stiffness, swelling and joint destruction. This joint pathology develops progressively and causes more discomfort than disabling. Psoriatic arthritis is considered seronegative spondyloarthropathies.

Learn more about therapeutic evaluation of psoriatic arthritis @ Psoriatic arthritis preclinical and discovery stage products

Profile of emerging drugs for psoriatic arthritis

• ABT-494: Abbvie
• Risankizumab: Abbvie

Therapeutic Evaluation of Pipeline for Psoriatic Arthritis

There are approx. More than 50 key companies developing therapies for psoriatic arthritis. Companies that have their psoriatic arthritis drug candidates at the most advanced stage, i.e. registered, include Abbvie.

Learn more about emerging therapies in development for psoriatic arthritis @ Evaluation of clinical trials on psoriatic arthritis

Scope of the report in progress on psoriatic arthritis

• Coverage - Global
• Therapeutic evaluation of psoriatic arthritis by product type: mono, combination, mono/combination
• Psoriatic ArthritisTherapeutic Evaluation by Clinical Stages: Discovery, Preclinical, Phase I, Phase II, Phase III
• Psoriatic arthritis companies: Mylan, Celltrion, Fresenius Kabi, Pfizer, Fujifilm Kyowa Kirin Biologics, Amgen, Zydus cedilla, Sandoz, Shanghai Henlius Biotech, Hetero Biopharma, CinnaGen, Fresenius Kabi, Torrent Pharmaceuticals, Cipla, Biogen, AbbVie, Biocad, Boehringer Ingelheim. , Sun Pharma Global, Gilead Sciences, UCB Biopharma, Formycon, Bristol-Myers Squibb, AbGenomics, Boehringer Ingelheim, Affibody, AltruBio, Bio-Thera Solutions, Dong-A ST, Synact Pharma, NeuClone, 3SBio, Qyuns Therapeutics, Kangpu Biopharmaceuticals, Alpine Immune Sciences, Akeso Biopharma, Polpharma Biologics, Avotres, Bio-Thera Solutions, Xbrane Biopharma, XBiotech, Innovimmune Biotherapeutics, Aclaris Therapeutics, Luye Pharma Group, Evelo, Levolta Pharmaceuticals, DNX Biopharmaceuticals, Mycenax Biotech and others.
• Therapies in progress for psoriatic arthritis: NDI-034858, alefacept, methotrexate, etanercept, UCB4940 40 mg, methotrexate (MTX), and others.

Delve into valuable information about new medications for the treatment of psoriatic arthritis, visit @ Psoriatic Arthritis Market Drivers and Barriers, and Future Prospects

Table of Contents

1. Introduction
2. Executive Summary
3. Psoriatic arthritis: overview
4. Pipeline Therapeutics
5. Therapeutic evaluation
6. Psoriatic Arthritis: DelveInsight Analytics Perspective
7. In-depth business evaluation
8. Partnership Offers for Psoriatic Arthritis
9. Products in advanced stage (registered/launched)
10. MYL-1401A: Mylan
11. Drug profiles in the detailed report…..
12. Products in advanced stage (registered)
13. ABT-494: Abbvie
14. Drug profiles in the detailed report…..
15. Products in advanced stage (pre-registration)
16. Tildrakizumab: Sun Pharma Global
17. Drug profiles in the detailed report…..
18. Late stage products (Phase III)
19. Filgotinib: Gilead Sciences
20. Drug profiles in the detailed report…..
21. Mid-stage products (Phase II)
22. PF-06700841: Pfizer
23. Drug profiles in the detailed report…..
24. Early stage products (Phase I)
25. BAT2506: Bio-Thera Solutions
26. Drug profiles in the detailed report…..
27. IND stage products
28. KPG-612: Kangpu Biopharmaceuticals
29. Drug profiles in the detailed report…..
30. Products in preclinical stage
31. ALPN 101: Alpine Immune Sciences
32. Drug profiles in the detailed report…..
33. Discovery Stage Products
34. DNX 514: DNX Biopharmaceuticals
35. Inactive products
36. Key Psoriatic Arthritis Companies
37. Key products for psoriatic arthritis
38. Psoriatic arthritis: unmet needs
39. Psoriatic Arthritis: Market Drivers and Barriers
40. Psoriatic arthritis: future perspectives and conclusion
41. Analyst Views of Psoriatic Arthritis
42. Key Psoriatic Arthritis Companies
43. Appendix

For more information about therapies in the works for psoriatic arthritis, contact Unmet needs and analyst opinions on psoriatic arthritis

About us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and deep knowledge of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients around the world. Connect with us to get high-quality, accurate, real-time intelligence to stay ahead of the growth curve.

Media contact
Company Name: DelveInsight Business Research LLP
Contact person: Yash Bhardwaj
Email: Send an e-mail
Phone: 9193216187
ADDRESS:304 S. Jones Blvd. #2432
City: Las Vegas
State: Snowfall
Country: USA
Website: https://www.delveinsight.com/consulting/ci-tracking